Skip to main content
NCBI home page
Atencion Primaria logoLink to Atencion Primaria
. 2008 Dec 10;35(7):348–352. [Article in Spanish] doi: 10.1157/13074292

Uso de hipoglucemiantes orales en pacientes con diabetes mellitus tipo 2

Use of oral lipid-lowering drugs in patients with type-2 diabetes mellitus

A Gómez García a,⁎, JG Soto Paniagua b, C Álvarez Aguilar c
PMCID: PMC7684331  PMID: 15871795

Abstract

Objective

To investigate whether oral lipid-lowering drugs (OLL) are used in line with the Mexican Official Regulation (NOM)- 015-SSA-1994 for preventing, treating, and monitoring diabetes mellitus 2 (DM2) patients.

Design

Observational, descriptive study.

Setting

Primary care. Unit of Family Medicine (UMF) No. 80 of the Mexican Social Security Institute.

Participants

332 patients diagnosed with DM2, taking pharmacological treatment and with recent laboratory studies.

Main measurements

Age, body mass index (BMI), years of evolution of diabetes, type of medication and OLL dose, time taking OLL, glucose, total cholesterol, and triglycerides. The patients were divided into 2 groups on the basis of the BMI: group 1 with BMI<27; group 2 ≥27. In addition, each group was subdivided by the type of medication.

Results

Glibenclamide was the OLL most prescribed (52% in both groups). In group 1 there were significant intra-group differences between patient's age and years of evolution of diabetes, whereas in group 2 only the metformin sub-group was associated with lower glucose concentrations and higher concentrations of triglycerides than in the other sub-groups. All patients had deficient glucaemia control.

Conclusions

The data show that OLL treatment for DM2 patients varied from the NOM. Unification of criteria in primary care for the prescription pattern and the use of OLL for better metabolic control of this kind of patient were recommended.

Key words: Oral lipid-lowering drugs, Type-2 diabetes mellitus, Primary care

Bibliografía

  • 1.Zimmet P., Alberti K., Shaw J. Global and social implications of the diabetes epidemic. Nature. 2001;414:782–787. doi: 10.1038/414782a. [DOI] [PubMed] [Google Scholar]
  • 2.Aguilar-Salinas C.A., Rojas R., Gómez-Pérez F.J., García E., Valles V., Ríos-Torres J.M. Prevalence and characteristics of earlyonset type 2 diabetes in México. Am J Med. 2002;113:569–574. doi: 10.1016/s0002-9343(02)01314-1. [DOI] [PubMed] [Google Scholar]
  • 3.Olaiz G., Rojas R., Barquera S., Shamah T., Aguilar C., Cravioto P. Instituto Nacional de Salud Pública; Cuernavaca: 2003. Encuesta Nacional de Salud 2000. Tomo 2. La salud de los adultos. [Google Scholar]
  • 4.American Diabetes Association Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2004;27(1):S33–S43. doi: 10.2337/diacare.17.6.616. [DOI] [PubMed] [Google Scholar]
  • 5.UK Prospective Diabetes Study (UKPDS) Group: intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet. 1998;352:837–853. [PubMed] [Google Scholar]
  • 6.Harris M.I., Flegal K.M., Eastman R.C., Eberhardt M.S., Cowie C.C. Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care. 1999;22:403–408. doi: 10.2337/diacare.22.3.403. [DOI] [PubMed] [Google Scholar]
  • 7.Campbell I.W. Antidiabetic drugs present and future: will improving insulin resistance benefit cardiovascular risk in type 2 diabetes mellitus? Drugs. 2000;60:1017–1028. doi: 10.2165/00003495-200060050-00004. [DOI] [PubMed] [Google Scholar]
  • 8.Cañedo Dorantes L. Tamaño de muestra. In: Cañedo Dorantes L., editor. Investigación clínica. 1.ª ed. Editorial Nueva Editorial Interamericana, S.A.; México D.F: 1987. pp. 171–183. [Google Scholar]
  • 9.Lerman-Garber I., Rull Rodrigo J.A. Epidemiology of diabetes in México and associated coronary risk factors. IMAJ. 2001;3:369–373. [PubMed] [Google Scholar]
  • 10.Riddle M.C. Oral pharmacologic management of type 2 diabetes. Am Fam Physician. 1999;60:2613–2620. [PubMed] [Google Scholar]
  • 11.White J.R. The pharmacological management of patients with type II diabetes mellitus in era of new oral agents and insulin analogs. Diabetes Spectrum. 1996;9:227–234. [Google Scholar]
  • 12.Inzucchi SE. Oral antihypeglycemic therapy for type 2 diabetes. Scientific Review. JAMA. 202;287:360-72. [DOI] [PubMed]
  • 13.Goday Arno A., Mata Cases M. La terapia combinada en la diabetes mellitus tipo 2. Criterios y pautas. Documentos de consenso del proyecto COMBO. Medicina Integral. 2001;38:270–289. doi: 10.1016/S0212-6567(01)78797-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Mooradian A.D. Drug therapy of non-insulin-dependent diabetes mellitus in elderly. Drugs. 1996;51:931–941. doi: 10.2165/00003495-199651060-00002. [DOI] [PubMed] [Google Scholar]
  • 15.Riddle M. Combining sulphonylureas and others oral agents. Am J Med. 2000;108(6):S15–S22. doi: 10.1016/s0002-9343(00)00338-7. [DOI] [PubMed] [Google Scholar]
  • 16.Giugliano D., De Rosa N., Di Maro G., Marfelia R., Acampora R., Buoninconti R. Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care. 1993;16:1387–1390. doi: 10.2337/diacare.16.10.1387. [DOI] [PubMed] [Google Scholar]
  • 17.Nuttall F.Q. Comparison of percent total GHb with percent HbA1c in people with and without known diabetes. Diabetes. 1998;21:1475–1480. doi: 10.2337/diacare.21.9.1475. [DOI] [PubMed] [Google Scholar]

Articles from Atencion Primaria are provided here courtesy of Elsevier

RESOURCES